Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 7/2010

01-07-2010 | Research Articles

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01

Authors: Joaquim Bellmunt, Pablo Maroto-Rey, José M. Trigo, Joan Carles, Vicente Guillem, José A. López-Martín, Antonio Antón-Torres, Leyrer Urruticoechea

Published in: Clinical and Translational Oncology | Issue 7/2010

Login to get access
Metadata
Title
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01
Authors
Joaquim Bellmunt
Pablo Maroto-Rey
José M. Trigo
Joan Carles
Vicente Guillem
José A. López-Martín
Antonio Antón-Torres
Leyrer Urruticoechea
Publication date
01-07-2010
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 7/2010
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-010-0544-2

Other articles of this Issue 7/2010

Clinical and Translational Oncology 7/2010 Go to the issue

Editorial

Present and future of sentinel lymph node biopsy in breast cancer staging

Case Reports

Neuroendocrine small cell carcinoma of the uterine cervix

Educational Series

Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas

Special Article

Controversies on the management of clinical situations with low therapeutic effectiveness in oncology

News and Views

The art of providing care

Educational Series

Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits